{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-23-000048","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.279106+00:00","generated_at":"2026-06-18T23:48:01.147372+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Denali Therapeutics Q4 2022 net loss $98.7M; cash $1.34B; guides 2023 opex up 25-30%","bullets":["Net loss $98.7M in Q4 2022 vs $75.3M in Q4 2021; full year net loss $326.0M vs $290.6M.","Collaboration revenue $10.3M Q4, $108.5M FY2022; R&D expenses $92.1M Q4, $358.7M FY2022.","Cash and marketable securities $1.34B as of Dec 31, 2022; raised $296.2M net in Oct 2022 public offering.","2023 guidance: cash operating expenses expected to increase 25-30% YoY, partially offset by up to $50M in partnership payments.","Phase 2/3 COMPASS study for DNL310 (MPS II) enrolling; Phase 3 LIGHTHOUSE for BIIB122 (Parkinson's) initiated; Phase 2 HIMALAYA for DNL788 (ALS) recruitment completion expected end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-23-000048","json":"https://secwatch.observer/filing/0001714899-23-000048.json","markdown":"https://secwatch.observer/filing/0001714899-23-000048.md","text":"https://secwatch.observer/filing/0001714899-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000048/0001714899-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000048/dnli-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:48:01.147372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a23c3dbfd017a512fe4e5b378ab60aa6e9d6b942","claim":"Denali Therapeutics Inc. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, Denali Therapeutics Inc. (the \"Company\") issued a press release announcing its financial results for the fourth quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000048/0001714899-23-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}